Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book
  1. Brieflands
  2. journals
  3. Gene, Cell and Tissue
  4. Articles

  5. Evaluation of 40-bp Insertion/Deletion Polymorphism of MDM2 and the Risk of Childhood Acute Lymphoblastic Leukemia
  6. Scopus by Title (Ref)

Gene, Cell and Tissue

The Official Journal of Zahedan University of Medical Sciences

homeHome
play_arrowCurrent Issuecheck_circleAccepted ManuscriptslistAll Issuesformat_indent_increaseIn PresssearchSearch
settingsInstructions
infoJournal InformationgroupsEditors & BoardsshareIndexing and Listing SourcesbalancePublication Ethics and Malpractice StatementschoolScientific CollaboratorsemailSupportassignment_indReviewer and AE Registration FormphoneContact Usbar_chartJournal Metricszoom_inOpen Peer Review (OPR)
credit_cardAPC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. The 40bp indel polymorphism Rs150550023 in the MDM2 promoter is associated with intriguing shifts in gene expression in the P53-MDM2 regulatory hub

- Miedl H. , et al.

2. The 40bp indel polymorphism of MDM2 increase the risk of cancer: An updated meta-analysis

- Moazeni-Roodi A. , et al.

HomeInstructionsAPC

Archives

  • Current Issue
  • Accepted Manuscripts
  • All Issues
  • In Press
  • Search

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Publication Ethics and Malpractice Statement
  • Scientific Collaborators
  • Support
  • Reviewer and AE Registration Form
  • Contact Us
  • Journal Metrics
  • Open Peer Review (OPR)
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.